Clinical-scale expansion of human cytomegalovirus-specific cytotoxic T lymphocytes from peripheral blood mononuclear cells requiring single-peptide stimulation and feeder cells but not additional antigen-presenting cells.
BACKGROUND
The aim of this study was to find a simple and feasible method for ex vivo expansion of human cytomegalovirus (HCMV)-specific cytotoxic T cells from peripheral blood mononuclear cells (PBMNCs) without the aid of exogenous antigen-presenting cells (APCs) such as cultured dendritic cells.


METHODS
PBMNCs from three HLA-A*2402-seropositive donors were stimulated with HCMV pp65(341-350) peptide on Day 1 and then cultured with interleukin-2 and allogeneic feeder cells for 3 to 4 weeks. HCMV peptide-specific T cells were purified with HLA-A*2402/pp65(341-350) tetramer on Days 12 to 13 and harvested on Days 23 to 27.


RESULTS
The initial numbers of PBMNCs were 2 x 10(7), 1.5 x 10(7), and 2.5 x 10(7) and the increases in HCMV peptide-specific T cells were 3.5 x 10(4)-, 2.0 x 10(3)-, and 1.1 x 10(3)-fold, respectively. The estimated final numbers of tetramer-positive cells were 9.1 x 10(7), 9.0 x 10(6), and 5.3 x 10(6), respectively. The purities of the tetramer-positive cell population in culture were 72.6, 75.0, and 80.9 percent, respectively. The cells killed peptide-pulsed B-lympoblastoid cell lines and secreted interferon-gamma in a HLA-restricted manner. They did not have natural killer cell activity or lymphokine activated killer cell activity. Most of them had an effector-memory phenotype. They did not express killer inhibitory receptors.


CONCLUSIONS
This method makes it possible to obtain more than 1 x 10(7) HCMV-specific T cells from approximately 2 x 10(7) to 5 x 10(7) PBMNCs without exogenous APCs such as cultured dendritic cells.
Hokkaido Red Cross Blood Center, Sapporo, Japan.
Hisako
H
Sakagawa
Hiroshi
H
Azuma
Mitsuhiro
M
Fujihara
Hisami
H
Ikeda
D000938:Antigen-Presenting Cells / Q000166:cytology / Q000276:immunology; D001782:Blood Donors; D002452:Cell Count; D018929:Cell Culture Techniques / Q000379:methods; D002469:Cell Separation / Q000379:methods; D006801:Humans; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000166:cytology*; D008213:Lymphocyte Activation / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology* / Q000821:virology*